We are live on ! Find out more
KA

Kinnevik AB Portfolio holdings

AUM $65.6M
1-Year Est. Return 25.95%
This Fund
S&P 500
This Quarter Est. Return
-21.75%
1 Year Est. Return
-25.95%
3 Year Est. Return
-51.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$71.1M
AUM Growth
-$9.42M
Cap. Flow
+$11.1M
Cap. Flow %
15.68%
Top 10 Hldgs %
100%
Holding
1
New
–
Increased
1
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
RXRX icon
Recursion Pharmaceuticals
RXRX
+$11.1M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RXRX icon
1
Recursion Pharmaceuticals
RXRX
$1.58B
$71.1M 100%
13,434,171
+1,528,503
+13% +$11.1M

Similar funds

TCP
Teleios Capital Partners Zug $65.7M AUM 48.76% 1-Year Est. Return
MMC
Mainsail Management Company Austin, Texas $66M AUM 18.6% 1-Year Est. Return
MIG
Mithril II GP Austin, Texas $64.5M AUM 360.75% 1-Year Est. Return
KAM
Kinney Asset Management Chicago, Illinois $67.1M AUM 29.09% 1-Year Est. Return
MA
MAS Advisors Miami, Florida $63.2M AUM 9.63% 1-Year Est. Return
EVP
Evergreen Venture Partners Tel Aviv, Israel $68.4M AUM 1.49% 1-Year Est. Return
TIM
Tikehau Investment Management Paris, France $68.4M AUM 23.35% 1-Year Est. Return
A
Atomvest Hong Kong $68.5M AUM 4.6% 1-Year Est. Return

Kinnevik AB's Q1 2025 Portfolio in Review

As of Q1 2025, Kinnevik AB held 1 position worth $71.1M, down 12% from $80.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Kinnevik AB deployed $11.1M of net new capital in Q1 2025, adding to 1 existing holding.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Kinnevik AB added most to Recursion Pharmaceuticals in Q1 2025, an estimated $11.1M increase.
  • Kinnevik AB's ten largest holdings make up 100% of its $71.1M portfolio in Q1 2025.
  • Kinnevik AB opened 0 new positions and closed 0 in Q1 2025.
  • Kinnevik AB's portfolio value fell 12% quarter-over-quarter to $71.1M.

Based on Kinnevik AB's 13F filing for Q1 2025, filed 28 Apr 2025.